AI assistant
ABBOTT LABORATORIES — Director's Dealing 2022
Feb 24, 2022
29777_dirs_2022-02-23_101c5887-29a7-4cbc-8314-a12597191871.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2022-02-18
Reporting Person: PEDERSON MICHAEL J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-18 | Common shares without par value | A | 8735 | — | Acquired | 71306 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-18 | Option (right to buy) | $117.58 | A | 40710 | Acquired | 2032-02-17 | Common Shares (40710) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common shares without par value | 75 | Indirect |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,570 on February 18, 2023, 13,570 on February 18, 2024, and 13,570 on February 18, 2025.